United Kingdom

People: Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

9:00pm BST
Change (% chg)

$0.59 (+2.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Nicklasson, Alf 

Dr. Alf Gunnar Martin (Martin) Nicklasson, Ph.D. has been Independent Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Martin has held broad-based executive experience from positions in European pharmaceutical and biotech companies. He held executive vice president positions at AstraZeneca PLC and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this, he held a number of leadership positions at AB Astra and Kabi Pharmacia AB. Martin Nicklasson is chairman of the board of Orexo AB and Kymab Ltd., as well as Board Member of Basilea Pharmaceutica Ltd. He is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

Basic Compensation

Total Annual Compensation, DKK 750,000
Restricted Stock Award, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 750,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --